Zobrazeno 1 - 10
of 447
pro vyhledávání: '"casirivimab"'
Autor:
Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Thachanun Porntharukcharoen, Supamas Sirisreetreerux, Thitapha Thongchai, Kamonwan Soonklang, Nithi Mahanonda
Publikováno v:
Journal of Infection and Public Health, Vol 17, Iss 7, Pp 102471- (2024)
Background: Neutralizing monoclonal antibodies (NMabs) are recognized for their efficacy against non-severe COVID-19. However, spike protein mutations may confer resistance. This study evaluates the effectiveness of favipiravir (FPV) versus NMabs in
Externí odkaz:
https://doaj.org/article/b1d68159212648619f06ac2992b72cf0
Publikováno v:
Heliyon, Vol 10, Iss 11, Pp e31737- (2024)
COVID-19 in pregnancy is associated with increased maternal morbidity and mortality as well as higher risk for hospitalization in intensive care unit and mechanical ventilation. We present a 38-year-old 21+5week pregnant unvaccinated woman with twins
Externí odkaz:
https://doaj.org/article/28b53ce7a224498e8ca7b1f8260ea99f
Autor:
Marina S. Lebedkina, Daria S. Fomina, Zinaida Y. Mutovina, Ulyana A. Mаrkina, Pavel O. Bogomolov, Vladimir P. Chulanov, Mariana A. Lysenko, Ekaterina I. Alexeeva
Publikováno v:
Терапевтический архив, Vol 95, Iss 6, Pp 494-499 (2023)
Aim. To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal antibodies MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with risk factors in real word settings. Materials and methods. A non-
Externí odkaz:
https://doaj.org/article/eb72a7ef09da4ff099f9522bed183bf7
Publikováno v:
Open Medicine, Vol 18, Iss 1, Pp 716-9 (2023)
Coronavirus disease 2019 (COVID-19) caused a progress in research to find a solution to this pandemic. Also, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevimab are antibodies comb
Externí odkaz:
https://doaj.org/article/91cb15e0f39e4fd3b3a6b01f032f2fe1
Autor:
Alessandro Cozzi-Lepri, Vanni Borghi, Salvatore Rotundo, Bianca Mariani, Anna Ferrari, Cosmo Del Borgo, Francesca Bai, Pietro Colletti, Piermauro Miraglia, Carlo Torti, Anna Maria Cattelan, Giovanni Cenderello, Marco Berruti, Carlo Tascini, Giustino Parruti, Simona Coladonato, Andrea Gori, Giulia Marchetti, Miriam Lichtner, Luigi Coppola, Chiara Sorace, Alessandra D'Abramo, Valentina Mazzotta, Giovanni Guaraldi, Erica Franceschini, Marianna Meschiari, Loredana Sarmati, Andrea Antinori, Emanuele Nicastri, Cristina Mussini
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionCasirivimab and imdevimab (CAS/IMV) are two non-competing, high-affinity human IgG1 anti-SARS-CoV-2 monoclonal antibodies, that showed a survival benefit in seronegative hospitalized patients with COVID-19. This study aimed to estimate th
Externí odkaz:
https://doaj.org/article/0b97388ee1594886bbcecb9b15b4c631
Autor:
Martin Heller, Clara Henrici, Judith Büttner, Sebastian Leube, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka Schanz, Agnes Hallier, Eva Herrmann, Michael Schmidt, Christoph Sarrazin
Publikováno v:
International Journal of Infectious Diseases, Vol 129, Iss , Pp 260-265 (2023)
Objectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Me
Externí odkaz:
https://doaj.org/article/b89c38cffdf0416ba36498e3a5265dba
Publikováno v:
Heliyon, Vol 9, Iss 12, Pp e22839- (2023)
Background: The advantages and disadvantages of casirivimab-imdevimab for coronavirus disease 2019 are not well understood. We conducted a systematic review and meta-analysis of relevant literature to determine the therapeutic effectiveness and poten
Externí odkaz:
https://doaj.org/article/5ddd4ad193a44e5eb42313e781070e4c
Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
Autor:
Judith Pannier, Norbert Nass, Mohamad-Kamal Yaakoub, Florian Michael Maria Stelzner, Susann Veit, Margarita Kalomoiri, Mahdi Yassine, Gerhard Behre
Publikováno v:
Infectious Disease Reports, Vol 15, Iss 1, Pp 125-131 (2023)
Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect
Externí odkaz:
https://doaj.org/article/b1d6137d5f0f40ada547d2b6a54e2730
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, Wenjun Zheng, Scott Rasmussen, Danielle Armas, Masaru Oshita, Cynthia Brinson, Steven Folkerth, Lori Faria, Ingeborg Heirman, Neena Sarkar, Bret J. Musser, Shikha Bansal, Meagan P. O'Brien, Kenneth C. Turner, Samit Ganguly, Adnan Mahmood, Ajla Dupljak, Andrea T. Hooper, Jennifer D. Hamilton, Yunji Kim, Bari Kowal, Yuhwen Soo, Gregory P. Geba, Leah Lipsich, Ned Braunstein, George D. Yancopoulos, David M. Weinreich, Gary A. Herman
Publikováno v:
International Journal of Infectious Diseases, Vol 122, Iss , Pp 585-592 (2022)
Objectives: A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) in uninfected adult volunteers
Externí odkaz:
https://doaj.org/article/2e38e7074cf04400bb5312a6c93e1302